Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a debilitating cutaneous disease characterized by a vicious cycle of chronic inflammation and tissue destruction that stems from disruption of the skin microbiome and abnormal activation of both the innate and adaptive immune system. A hallmark of HS pathophysiology...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Immuno |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5601/4/1/4 |
| _version_ | 1797240617399484416 |
|---|---|
| author | Rene Chen Robyn Guo Amy J. Petty Tarannum Jaleel |
| author_facet | Rene Chen Robyn Guo Amy J. Petty Tarannum Jaleel |
| author_sort | Rene Chen |
| collection | DOAJ |
| description | Hidradenitis Suppurativa (HS) is a debilitating cutaneous disease characterized by a vicious cycle of chronic inflammation and tissue destruction that stems from disruption of the skin microbiome and abnormal activation of both the innate and adaptive immune system. A hallmark of HS pathophysiology is dysregulation of both the innate and adaptive immune system. The role of immune system dysregulation in HS development has motivated researchers to explore the utility of biologic immunomodulators. In 2015, adalimumab, a tumor necrosis factor-α inhibitor, was approved by the Food and Drug Administration (FDA) for treatment of moderate-to-severe HS in the US. In 2023, secukinumab, an interleukin-17A (IL-17A) inhibitor, was approved by the European Medicines Agency for treatment of moderate-to-severe HS in Europe. Ongoing clinical trials have shown promising clinical responses to targeted therapies against other pro-inflammatory cytokines including IL-17, IL-12, IL-1, IL-36, IL-6, IL-10, interferon γ, C5a, and Janus kinase (JAK). We provide an update on the efficacy and clinical usage of targeted biologics in HS treatment. |
| first_indexed | 2024-04-24T18:10:17Z |
| format | Article |
| id | doaj.art-6bc430173e5f4f198c551fdf6d40714a |
| institution | Directory Open Access Journal |
| issn | 2673-5601 |
| language | English |
| last_indexed | 2024-04-24T18:10:17Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Immuno |
| spelling | doaj.art-6bc430173e5f4f198c551fdf6d40714a2024-03-27T13:46:46ZengMDPI AGImmuno2673-56012024-02-0141577610.3390/immuno4010004Immune Dysregulation and Current Targeted Biologics in Hidradenitis SuppurativaRene Chen0Robyn Guo1Amy J. Petty2Tarannum Jaleel3School of Medicine, Duke University, Durham, NC 27710, USASchool of Medicine, Duke University, Durham, NC 27710, USADepartment of Dermatology, Duke University, Durham, NC 27710, USADepartment of Dermatology, Duke University, Durham, NC 27710, USAHidradenitis Suppurativa (HS) is a debilitating cutaneous disease characterized by a vicious cycle of chronic inflammation and tissue destruction that stems from disruption of the skin microbiome and abnormal activation of both the innate and adaptive immune system. A hallmark of HS pathophysiology is dysregulation of both the innate and adaptive immune system. The role of immune system dysregulation in HS development has motivated researchers to explore the utility of biologic immunomodulators. In 2015, adalimumab, a tumor necrosis factor-α inhibitor, was approved by the Food and Drug Administration (FDA) for treatment of moderate-to-severe HS in the US. In 2023, secukinumab, an interleukin-17A (IL-17A) inhibitor, was approved by the European Medicines Agency for treatment of moderate-to-severe HS in Europe. Ongoing clinical trials have shown promising clinical responses to targeted therapies against other pro-inflammatory cytokines including IL-17, IL-12, IL-1, IL-36, IL-6, IL-10, interferon γ, C5a, and Janus kinase (JAK). We provide an update on the efficacy and clinical usage of targeted biologics in HS treatment.https://www.mdpi.com/2673-5601/4/1/4immune dysregulationbiologicshidradenitis suppurativaadalimumabinfliximabsecukinumab |
| spellingShingle | Rene Chen Robyn Guo Amy J. Petty Tarannum Jaleel Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa Immuno immune dysregulation biologics hidradenitis suppurativa adalimumab infliximab secukinumab |
| title | Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa |
| title_full | Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa |
| title_fullStr | Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa |
| title_full_unstemmed | Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa |
| title_short | Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa |
| title_sort | immune dysregulation and current targeted biologics in hidradenitis suppurativa |
| topic | immune dysregulation biologics hidradenitis suppurativa adalimumab infliximab secukinumab |
| url | https://www.mdpi.com/2673-5601/4/1/4 |
| work_keys_str_mv | AT renechen immunedysregulationandcurrenttargetedbiologicsinhidradenitissuppurativa AT robynguo immunedysregulationandcurrenttargetedbiologicsinhidradenitissuppurativa AT amyjpetty immunedysregulationandcurrenttargetedbiologicsinhidradenitissuppurativa AT tarannumjaleel immunedysregulationandcurrenttargetedbiologicsinhidradenitissuppurativa |